DK3758732T3 - PD-1-peptidinhibitorer - Google Patents

PD-1-peptidinhibitorer Download PDF

Info

Publication number
DK3758732T3
DK3758732T3 DK18712047.2T DK18712047T DK3758732T3 DK 3758732 T3 DK3758732 T3 DK 3758732T3 DK 18712047 T DK18712047 T DK 18712047T DK 3758732 T3 DK3758732 T3 DK 3758732T3
Authority
DK
Denmark
Prior art keywords
peptide inhibitors
peptide
inhibitors
Prior art date
Application number
DK18712047.2T
Other languages
English (en)
Inventor
Gabriel M Gutierrez
Vinayaka Kotraiah
James Pannucci
Ramses Ayala
Original Assignee
Leidos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/906,481 external-priority patent/US10799555B2/en
Application filed by Leidos Inc filed Critical Leidos Inc
Application granted granted Critical
Publication of DK3758732T3 publication Critical patent/DK3758732T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK18712047.2T 2018-02-27 2018-02-28 PD-1-peptidinhibitorer DK3758732T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/906,481 US10799555B2 (en) 2016-09-15 2018-02-27 PD-1 peptide inhibitors
PCT/US2018/020209 WO2019168524A1 (en) 2018-02-27 2018-02-28 Pd-1 peptide inhibitors

Publications (1)

Publication Number Publication Date
DK3758732T3 true DK3758732T3 (da) 2024-10-07

Family

ID=61691571

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18712047.2T DK3758732T3 (da) 2018-02-27 2018-02-28 PD-1-peptidinhibitorer

Country Status (7)

Country Link
EP (1) EP3758732B1 (da)
JP (2) JP7170737B2 (da)
AU (1) AU2018410849B2 (da)
CA (1) CA3091414A1 (da)
DK (1) DK3758732T3 (da)
FI (1) FI3758732T3 (da)
WO (1) WO2019168524A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111205351B (zh) * 2020-01-19 2022-07-12 中国药科大学 一种pd-1靶向阻断肽及其应用
JP2023548662A (ja) * 2020-10-12 2023-11-20 レイドス， インコーポレイテッド 免疫調節性ペプチド
CN112266899A (zh) * 2020-10-26 2021-01-26 北京卡替医疗技术有限公司 修饰的免疫细胞及其用途
CN116063401B (zh) * 2021-08-13 2023-12-01 中国人民解放军总医院 阻断型靶向pd-l1的超高亲和力小蛋白及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL345241A1 (en) 1998-05-06 2001-12-03 Upjohn Co Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
EP1685159B1 (en) 2003-10-03 2012-08-01 Brigham & Women's Hospital Tim-3 polypeptides
IN2012DN00863A (da) 2009-07-31 2015-07-10 Medarex Inc
CA2790134A1 (en) * 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
MX342017B (es) 2010-03-26 2016-09-09 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
WO2012055015A1 (en) 2010-10-26 2012-05-03 Alberta Health Services Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
LT2904011T (lt) 2012-10-02 2017-11-10 Bristol-Myers Squibb Company Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui
WO2014127917A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
CN104072615B (zh) 2014-01-26 2016-08-24 中国人民解放军军事医学科学院基础医学研究所 一种能阻断Tim-3信号通路的人Tim-3融合蛋白
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
SG10201806297VA (en) 2014-02-04 2018-08-30 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
JP6613312B2 (ja) 2014-10-14 2019-11-27 ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ 膵臓癌を処置するためのペプチドをベースとする方法
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US9957325B2 (en) 2015-10-13 2018-05-01 Formurex, Inc. Synthetic antibody mimic peptides
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP6928083B2 (ja) * 2016-09-15 2021-09-01 レイドス， インコーポレイテッド Ｐｄ−１ペプチド阻害剤
CN107383174B (zh) * 2017-08-21 2019-01-18 生工生物工程（上海）股份有限公司 一种能与pd-1特异性结合的肿瘤抑制肽及其用途

Also Published As

Publication number Publication date
WO2019168524A1 (en) 2019-09-06
EP3758732A1 (en) 2021-01-06
JP2021514632A (ja) 2021-06-17
AU2018410849B2 (en) 2025-02-27
CA3091414A1 (en) 2019-09-06
AU2018410849A1 (en) 2020-09-10
JP2022190026A (ja) 2022-12-22
JP7170737B2 (ja) 2022-11-14
EP3758732B1 (en) 2024-07-24
FI3758732T3 (fi) 2024-10-25

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
EP4007752C0 (en) Kif18a inhibitors
MA54550A (fr) Inhibiteurs de kif18a
EP4007753C0 (en) Kif18a inhibitors
EP4007756C0 (en) KIF18A INHIBITORS
EP3843714C0 (en) CD73 INHIBITORS
EP4029868B1 (en) MCL-1 INHIBITORS
IL269196A (en) Novel inhibitors
MA52812A (fr) Inhibiteurs de sarm1
MA52413A (fr) Inhibiteurs de cd73
MA52813A (fr) Inhibiteurs de sarm1
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
MA52809A (fr) Inhibiteurs de sarm1
EP3980011C0 (en) SARM1 HIBITORS
DK3571192T3 (da) Jak1-selektive inhibitorer
EP3787635A4 (en) CD73 INHIBITORS
DK3774817T3 (da) Bcl6-hæmmere
DK4051688T3 (da) Cd73-hæmmere
EP3817736A4 (en) PIKFYVE INHIBITORS
PT3746446T (pt) Inibidores de prc2
IL280950A (en) Inhibitors of keap1-nrf2 protein-protein interaction
EP3788039C0 (en) FACTOR XIIA INHIBITORS
EP3773537A4 (en) STAT3 INHIBITORS
DK3795167T3 (da) Pd-1-peptidinhibitorer
DK3630744T3 (da) Pyrazol-magl-inhibitorer